Medicinova (MNOV) 3.67 $MNOV MN-166 (ibudilast) ALS

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Medicinova (MNOV) 3.67 $MNOV

MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 26th International Symposium on ALS/MND in Orlando, FL: Interim Safety and Clinical Outcomes to be Presented
GlobeNewswire - Tue Jul 28, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova's ongoing clinical trial of MN-166 (ibudilast) in ALS has been accepted for presentation at the 26th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held December 11-13, 2015 in Orlando, FL. Principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System's Neuromuscular/ALS-MDA Center, will present interim data from the ongoing study.
MNOV: 3.67 (+0.02)

MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia
GlobeNewswire - Mon Jul 27, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) has approved a second protocol for a clinical trial evaluating MN-001 (tipelukast) for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.
MNOV: 3.67 (+0.02)

MediciNova Announces Update on Development Plans for MN-001 in IPF
GlobeNewswire - Tue Jul 21, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is currently in late-stage discussions with investigators at Penn State University (principal investigator Dr. Rebecca Bascom) to conduct a Phase 2 study of MN-001 (tipelukast) for the treatment of moderate to severe IPF (idiopathic pulmonary fibrosis).
MNOV: 3.67 (+0.02)

Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
Seeking Alpha - at Seeking Alpha - Wed Jul 01, 10:30AM CDT

MNOV: 3.67 (+0.02), GLMD: 9.88 (-0.16), LJPC: 28.32 (-1.49), CNAT: 4.93 (-0.09), GALT: 2.64 (+0.03), RGLS: 8.35 (-0.57), DRRX: 2.30 (-0.19), RPTP: 14.05 (-0.04), GILD: 116.52 (+3.45), SHPG: 264.92 (+1.67), MRK: 58.59 (+1.07), AZN: 32.94 (+0.13), ICPT: 267.15 (-7.79), VBLT: 6.13 (-0.02), TBRA: 13.60 (-0.41)

MediciNova enrols 24 subjects under clinical trial of MN-166 (ibudilast) in alcohol dependence
M2 - Wed Jul 01, 3:44AM CDT
Biopharmaceutical company MediciNova (Nasdaq GM:MNOV) reported on Tuesday that it has completed enrollment in a clinical trial of 24 subjects in the study of MN-166 (ibudilast) in alcohol dependence.
MNOV: 3.67 (+0.02)

MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
GlobeNewswire - Tue Jun 30, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the clinical trial of MN-166 (ibudilast) in alcohol dependence has completed enrollment of 24 subjects.
MNOV: 3.67 (+0.02)

How To Make Money In Small To Nano-Cap Biotech
Scrying Biotech - at Seeking Alpha - Wed Jun 24, 12:55PM CDT

SGYP: 8.15 (-0.09), TRVN: 6.05 (-0.18), OCAT: 4.27 (-0.15), MNOV: 3.67 (+0.02), SGEN: 47.30 (-1.63), NVAX: 11.86 (-0.33), NKTR: 12.34 (-0.54)

MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting
GlobeNewswire - Wed Jun 24, 8:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that principal investigator Lara Ray, Ph.D., Associate Professor, Department of Psychology, Brain Research Institute at University of California Los Angeles, gave a RSA 2014 Young Investigator Awardee presentation today at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting in San Antonio, TX entitled "A RESEARCH AGENDA ON THE CLINICAL NEUROSCIENCE OF ALCOHOLISM." At the request of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the sponsor of the study, the presentation included preliminary interim data from the first 22 subjects in the ongoing clinical trial of MN-166 (ibudilast) in alcohol dependence. Dr. Ray commented "MN-166 (ibudilast) was very well tolerated and there were no drug-related drop outs or serious adverse events. The preliminary results indicate that ibudilast has beneficial effects on mood (p<0.05), decreased the daily measure of alcohol craving (p=0.05), and potentiated alcohol-induced sedation (p<0.05)."
MNOV: 3.67 (+0.02)

MediciNova Is An Excellent Opportunity In The Biotech Space
Emerging Equities - at Seeking Alpha - Mon Jun 22, 1:34PM CDT

MNOV: 3.67 (+0.02), IPF: 21.79 (+0.07)

MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology
GlobeNewswire - Tue Jun 16, 5:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Addiction Biology has published a new article on MN-166 (ibudilast) entitled "The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers." The article was written by Ziva D. Cooper, Sandra D. Comer, and other colleagues at Columbia University and New York State Psychiatric Institute. The article discusses results of a clinical study which investigated the dose-dependent effects of MN-166 (ibudilast), a glial cell modulator, on withdrawal symptoms in opioid-dependent volunteers after abrupt discontinuation of morphine administration.
MNOV: 3.67 (+0.02)

MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
GlobeNewswire - Fri Jun 12, 4:59AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the ongoing clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) has completed randomization of 255 subjects, which exceeds the goal of 250 subjects that were planned for participation. NINDS (National Institute of Neurological Disorders and Stroke) is planning to conduct an interim efficacy analysis after half the subjects complete the 96-week treatment period, which analysis is expected to occur in the fall of 2016.
MNOV: 3.67 (+0.02)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 8:14AM CDT

PBMD: 1.32 (-0.02), MNOV: 3.67 (+0.02), SYN: 3.28 (-0.07), HALO: 23.19 (-0.52), SNCR: 46.78 (+2.51), ORIG: 4.25 (+0.26), CDTI: 1.73 (+0.03), GIII: 68.96 (-0.38), VRA: 11.00 (+0.21), VMEM: 2.34 (+0.17)

MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
GlobeNewswire - Wed Jun 03, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to MN-166 (ibudilast) for treatment of Krabbe disease. MediciNova previously opened an Investigational New Drug (IND) application with the Division of Neurology Products (DNP) for MN-166 (ibudilast).
MNOV: 3.67 (+0.02)

Acucela names Shintaro Asako to board
M2 - Tue May 19, 4:39AM CDT
Acucela Inc (Tokyo:4589) , a clinical-stage biotechnology company specialising in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced on Tuesday that Shintaro Asako has been nominated to stand for election to the company's board of directors at the 2015 Annual Meeting of Shareholders on 25 June 2015.
MNOV: 3.67 (+0.02)

Seeking Alpha's Biotech Weekly: Celgene's Future, Northwest Bio's Science, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 08, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CYTK: 7.03 (-0.37), NWBO: 11.42 (-0.58), MNOV: 3.67 (+0.02), ACT: 298.98 (-2.94), MDT: 77.36 (-0.11), OVAS: 27.97 (-2.52), AMRN: 2.21 (+0.06), XBI: 251.86 (-7.08), AERI: 18.53 (-0.61), IBB: 376.37 (-6.47), SPA: 24.05 (+0.27), NDRM: 18.96 (-0.14), GEVA: 238.60 (+2.80), QURE: 25.44 (-0.74), ACRX: 4.00 (unch), SSH: 3.15 (+0.13), VRTX: 126.87 (-1.43), GSK: 42.78 (+1.07), BMY: 64.46 (-0.20), CELG: 132.88 (-2.54), GILD: 116.52 (+3.45), ALXN: 201.61 (-1.94), SCMP: 21.75 (-0.96), OHRP: 3.05 (-0.11), NVS: 103.78 (+0.99)

Ibudilast Phase 2 study fully enrolled; randomization to be completed in 4 - 6 weeks
Seeking Alpha - at Seeking Alpha - Thu May 07, 7:28AM CDT

MNOV: 3.67 (+0.02)

MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
GlobeNewswire - Thu May 07, 7:00AM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has been notified by NINDS (National Institute of Neurological Disorders and Stroke) that the ongoing clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) is now fully enrolled. Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study. Randomization is expected to be completed in approximately 4 - 6 weeks.
MNOV: 3.67 (+0.02)

MediciNova's Deep Pipeline Is Meaningfully Undervalued
Jason Napodano, CFA - Seeking Alpha - Wed May 06, 2:57PM CDT
By Jason Napodano, CFA & David Bautz, PhD We are initiating coverage of MediciNova, Inc. (NASDAQ: MNOV ) with a Buy rating and an $8.00 price target. MediciNova is a biopharmaceutical company focused on developing small molecule therapeutics for...
MNOV: 3.67 (+0.02)

BUYINS.NET: ATVI, SHM, JXI, MNOV, ADK, BGS Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 29, 7:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Activision Blizzard Inc (NASDAQ:ATVI), SPDR Nvn Barclys Cptl Shrt Trm Mncpl Bnd (NYSE:SHM), iShares S&P Global Utilities Sector Index Fund (NYSE:JXI), MediciNova Inc (NASDAQ:MNOV), ADCARE HEALTH SYSTEMS INC (NYSE:ADK), B&G Foods Inc (NYSE:BGS) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ATVI: 25.92 (+0.21), MNOV: 3.67 (+0.02), JXI: 45.53 (-0.07), BGS: 29.68 (+0.41), SHM: 24.32 (-0.01), ADK: 3.70 (-0.02)

Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting
GlobeNewswire - Thu Apr 23, 6:00PM CDT
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Robert J. Fox from the Cleveland Clinic, principal investigator of MediciNova's ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS), made a presentation today at the American Academy of Neurology (AAN) 67th Annual Meeting in Washington, DC. The presentation included baseline characteristics for the first 228 subjects that were enrolled and randomized in the study as of April 6, 2015. A total of 250 subjects are planned for participation.
MNOV: 3.67 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 97

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 302

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 158

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 216

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Blend's AWS Financial Services Competency Enhances Innovations

Updated Category News Views 152

Blend Takes a Major Stride with AWS Financial Services Competency Exciting news emerges from Blend as the company secures a crucial recognition in the cloud technology arena. They've recently achieved the prestigious AWS Financial Services Competency badge, a testament to their outstanding expertise and remarkable track record in delivering innovative, secure, and...

Continue Reading
The Upcoming Surge of Last Mile Delivery Market Growth

Updated Category News Views 289

Overview of the Last Mile Delivery Market Growth The Last Mile Delivery market is poised for significant growth in the coming years, projected to rise by USD 51.1 billion from 2025 to 2029. This increase is primarily driven by the expanding global e-commerce sector and the integration of advanced technologies, including AI, which are transforming logistical operations....

Continue Reading
Tide Rock Expands Its Precision Machining Horizons Through Acquisitions

Updated Category News Views 326

Tide Rock Expands Its Precision Machining Horizons Tide Rock has taken a significant leap forward in the field of advanced precision machining through its recent acquisitions. By acquiring Precision Waterjet & Laser, now known as Precision Advanced Machining, located in Anaheim, California, and Made in America Manufacturing based in Buda, Texas, Tide Rock is enhancing its...

Continue Reading
Novavax Revises Projections, Anticipates Robust Nuvaxovid Demand

Updated Category News Views 149

Novavax Reports Strong Second Quarter Results Recently, Novavax Inc. reported impressive sales of $239.24 million for the second quarter of 2025, marking a significant shift from $415 million during the same period in the previous year. This figure exceeded the Wall Street consensus expectations, which estimated sales at $156.29 million. Such growth highlights Novavax's...

Continue Reading
Insights into Novartis' Cosentyx and GCAptAIN Study Findings

Updated Category News Views 219

Novartis' Groundbreaking Updates on Cosentyx in GCAptAIN Study Novartis has recently provided significant updates regarding the Phase III GCAptAIN study, focusing on the efficacy of Cosentyx (secukinumab) for patients suffering from giant cell arteritis (GCA). This condition, predominantly affecting older adults, poses a risk of severe complications if not managed...

Continue Reading